Mealey's (May 28, 2020, 10:03 AM EDT) -- WASHINGTON, D.C. — In a May 8 appellee brief, Sanofi Mature IP tells the Federal Circuit U.S. Court of Appeals that the Patent Trial and Appeal Board did not err in granting proposed substitute claims in a patent relating to treatment of prostate cancer (Mylan Laboratories Ltd. v. Sanofi Mature IP, No. 20-1302, Fed. Cir.)....